Post by
postie1 on Jul 18, 2020 1:22pm
Less than 2 weeks
Acasti must have a good idea now of the data from TRILOGY 2 by now if they are going to have detailed report ready for the end of July.. As usual , watch the stock price and action. Maybe Friday was an early accidental leak.
"We are carefully considering the FDA’s comments on the TRILOGY 1 data, and are conducting further post-hoc analysis based on their feedback. Acasti will now finalize the Statistical Analysis Plan (SAP) for TRILOGY 2, which we plan to submit to the FDA by the end of July. We continue to remain blinded to the TRILOGY 2 data, and we continue to estimate that we should be able to report topline data by the end of August 2020. The key secondary and exploratory endpoints from both TRILOGY 1 and TRILOGY 2 trials would still be expected as soon as possible after the unblinding of TRILOGY 2 results.”